First Patients Dosed in Trial of Radioactive Antibody for Prostate, Other Cancers

First Patients Dosed in Trial of Radioactive Antibody for Prostate, Other Cancers
The first three patients have been dosed in a clinical trial evaluating the safety and tolerability of MILGa, a radioactive antibody designed to seek out and destroy cancerous tumors in advanced prostate, bladder, and pancreatic cancer. The patients — two with pancreatic cancer and one with prostate cancer — have completed a one-month follow-up, and no treatment-related side effects were reported, according to a press release from the treatment's developer, Minomic International. This first-in-human trial (ACTRN12616000787482) — which is being conducted after successful preclinical studies — is primarily examining the safety, tolerability and tumor-targeting ability of a chimeric version of Minomic's MIL-38 monoclonal antibody conjugated with the radioactive isotope 67-Gallium (MILGa). The single-arm trial is being conducted at Macquarie University’s private hospital in Sydney, Australia. MILGa will be evaluated based on several parameters: patients' vital signs, 12-lead electrocardiograms (ECGs) and blood draws, biomarker blood draws, an analysis of patients' urine, hematology and biochemistry blood analysis, and physical examinations. Secondary endpoints include evaluating MILGa as a diagnostic tool in prostate, bladder, and pancreatic tumors, and analyzing tumor images to determine how much MILGa accumulates in different organs. In preclinical studies, MILGa successfully targeted prostate, pancreatic, and bladder cancer cells. The experiments, which were conducted in mouse models, also show
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *